Health Economics›Pancreatic cancer›Induction therapy for locally advanced disease unresectable

Induction therapy for locally advanced disease unresectable

Pancreatic cancer · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Erlotinib and Gemcitabine Variant #03	—	R 55 934	56d	—	6.1 mo	—	—	2
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	5.7 mo	6.6 mo	4	R 56 851 PFS proxy	21
Gemcitabine and RT Variant #09	—	R 7 106	56d	—	15.7 mo	—	—	2
Fluorouracil and RT Variant #08	—	R 3 059	77d	—	10.0 mo	—	—	1
FLEC Variant #01	—	R 2 592	21d	—	7.9 mo	—	—	—
GemOx Variant #01	—	R 2 335	14d	5.8 mo	9.0 mo	13	R 30 358 PFS proxy	2
Capecitabine monotherapy Variant #17	—	R 2 219	21d	—	—	—	—	2
Radiation therapy N/A - radiation Partial	—	—	49d	—	~9.2 mo	—	—	1

8 of 8 regimens shown